<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00613834</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU FAMPLAN 3343</org_study_id>
    <nct_id>NCT00613834</nct_id>
  </id_info>
  <brief_title>Intrauterine Lidocaine Infusion for Essure Sterilization Procedures</brief_title>
  <official_title>Intrauterine Lidocaine Infusion for Pain Management During Outpatient Essure Transcervical Tubal Sterilization Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the level of pain women experience with an Essure
      procedure and the effect that lidocaine might have on that pain. We will also assess the
      absorption of lidocaine in the uterus by measuring lidocaine levels in the blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We intend to conduct a randomized, blinded, and placebo- controlled clinical trial at Oregon
      Health and Science University and Planned Parenthood of the Columbia Willamette to determine
      if intrauterine lidocaine infusion will decrease the amount of pain subjects experience
      during and after Essure transcervical tubal sterilization.

      We plan to enroll women who have selected Essure as their method of tubal sterilization who
      will be randomized to one of two groups on the days of their procedures. Subjects in Group 1,
      the treatment group, will receive a standard paracervical block with lidocaine intrauterine
      infusion and subjects in Group 2, the control group, will receive a standard paracervical
      block with saline intrauterine infusion. The subjects will be asked to rate their pain on a
      100 mm Visual Analog Scale (VAS) at five points during the procedure and once thirty minutes
      following the procedure. Subjects will also be asked to rate their overall satisfaction with
      their care prior to leaving the recovery room.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Patient-perceived Pain Between Baseline and Cannulization</measure>
    <time_frame>Immediately after speculum insertion and immediately after cannulization</time_frame>
    <description>Patients rated their pain following speculum insertion (used as baseline) and after insertion of a cannula into both fallopian tubes. Reported pain during cannulization of the right and left fallopian tubes were averaged to obtain the measurement of pain at cannulization. Pain was reported using a Visual Analog Scale (VAS, range 0-100), where a score of 0 indicates no pain and a score of 100 indicates the worst pain imaginable. Baseline pain levels were subtracted from average pain during cannulization: a negative change in VAS score between baseline and cannulization indicates less pain during cannulization and a positive change in VAS score indicates more pain during cannulization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Perceived Pain 30 Minutes Post-procedure</measure>
    <time_frame>30 minutes post-procedure</time_frame>
    <description>Patients rated their pain 30 minutes after speculum removal using a Visual Analog Scale (VAS, range 0-100), where a score of 0 indicates no pain and a score of 100 indicates the worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With the Essure Tubal Sterilization Procedure</measure>
    <time_frame>30 minutes post-procedure</time_frame>
    <description>Patients reported their overall satisfaction with the Essure tubal sterilization procedure using a Visual Analog scale (VAS), range 0-100. A score of 0 indicates lowest possible satisfaction and a score of 100 indicates highest possible satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Lidocaine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive transcervical instillation of 5 ml 4% lidocaine solution 3 minutes prior to transcervical tubal sterilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive transcervical instillation of 5 ml saline 3 minutes prior to transcervical tubal sterilization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes</description>
    <arm_group_label>Lidocaine group</arm_group_label>
    <other_name>Xylocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Saline</intervention_name>
    <description>5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Age 18 or older

          -  Good general health, based on the opinion of the investigator

          -  Voluntarily requesting permanent sterilization

          -  Negative pregnancy test

          -  Agree to premedication with ibuprofen and ativan

          -  English speaking, or other language if an interpreter is available to be present at
             all points of the study procedure.

          -  Willing and able to sign an informed consent

          -  Willing to comply with the terms of the study

        Exclusion Criteria:

          -  Significant physical or mental health condition, based on the opinion of the
             investigator.

          -  Positive pregnancy test

          -  Request for IV/IM sedation prior to the start of the procedure

          -  Refusal of ibuprofen, ativan, or paracervical block

          -  Allergy to any study medication including lidocaine, ibuprofen, ativan, sodium
             bicarbonate

          -  History of toxic reaction to local anesthetics

          -  Known hepatic disease or liver dysfunction. (Lidocaine is metabolized by the liver.)

          -  Weight less than 100 pounds. [Any patient weighing less than 100 pounds would receive
             more than the recommended dose for their weight (4.5 mg/kg or 2 mg/lb)].

          -  Current participation in another research study which would interfere with the conduct
             of this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle M. Isley, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood of the Columbia Willamette</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ohsuwomenshealth.com/research/index.html</url>
    <description>(Women's Health Research Unit website)</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>February 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <results_first_submitted>April 9, 2012</results_first_submitted>
  <results_first_submitted_qc>December 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2019</results_first_posted>
  <last_update_submitted>December 14, 2019</last_update_submitted>
  <last_update_submitted_qc>December 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Alison Edelman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Essure sterilization</keyword>
  <keyword>pain management</keyword>
  <keyword>intrauterine lidocaine infusion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lidocaine Group</title>
          <description>Participants receive transcervical instillation of 5 ml 4% lidocaine solution 3 minutes prior to transcervical tubal sterilization</description>
        </group>
        <group group_id="P2">
          <title>Saline Group</title>
          <description>Participants receive transcervical instillation of 5 ml saline 3 minutes prior to transcervical tubal sterilization</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lidocaine Group</title>
          <description>Participants receive transcervical instillation of 5 ml 4% lidocaine solution 3 minutes prior to transcervical tubal sterilization</description>
        </group>
        <group group_id="B2">
          <title>Saline Group</title>
          <description>Participants receive transcervical instillation of 5 ml saline 3 minutes prior to transcervical tubal sterilization</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.4" spread="6.6"/>
                    <measurement group_id="B2" value="33.8" spread="6.3"/>
                    <measurement group_id="B3" value="33.6" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Patient-perceived Pain Between Baseline and Cannulization</title>
        <description>Patients rated their pain following speculum insertion (used as baseline) and after insertion of a cannula into both fallopian tubes. Reported pain during cannulization of the right and left fallopian tubes were averaged to obtain the measurement of pain at cannulization. Pain was reported using a Visual Analog Scale (VAS, range 0-100), where a score of 0 indicates no pain and a score of 100 indicates the worst pain imaginable. Baseline pain levels were subtracted from average pain during cannulization: a negative change in VAS score between baseline and cannulization indicates less pain during cannulization and a positive change in VAS score indicates more pain during cannulization.</description>
        <time_frame>Immediately after speculum insertion and immediately after cannulization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Group</title>
            <description>Participants receive transcervical instillation of 5 ml 4% lidocaine solution 3 minutes prior to transcervical tubal sterilization</description>
          </group>
          <group group_id="O2">
            <title>Saline Group</title>
            <description>Participants receive transcervical instillation of 5 ml saline 3 minutes prior to transcervical tubal sterilization</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient-perceived Pain Between Baseline and Cannulization</title>
          <description>Patients rated their pain following speculum insertion (used as baseline) and after insertion of a cannula into both fallopian tubes. Reported pain during cannulization of the right and left fallopian tubes were averaged to obtain the measurement of pain at cannulization. Pain was reported using a Visual Analog Scale (VAS, range 0-100), where a score of 0 indicates no pain and a score of 100 indicates the worst pain imaginable. Baseline pain levels were subtracted from average pain during cannulization: a negative change in VAS score between baseline and cannulization indicates less pain during cannulization and a positive change in VAS score indicates more pain during cannulization.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" lower_limit="-7" upper_limit="73"/>
                    <measurement group_id="O2" value="35" lower_limit="-18.5" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perceived Pain 30 Minutes Post-procedure</title>
        <description>Patients rated their pain 30 minutes after speculum removal using a Visual Analog Scale (VAS, range 0-100), where a score of 0 indicates no pain and a score of 100 indicates the worst pain imaginable.</description>
        <time_frame>30 minutes post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Group</title>
            <description>Participants receive transcervical instillation of 5 ml 4% lidocaine solution 3 minutes prior to transcervical tubal sterilization
Lidocaine: 5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants receive transcervical instillation of 5 ml saline 3 minutes prior to transcervical tubal sterilization
Sterile Saline: 5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perceived Pain 30 Minutes Post-procedure</title>
          <description>Patients rated their pain 30 minutes after speculum removal using a Visual Analog Scale (VAS, range 0-100), where a score of 0 indicates no pain and a score of 100 indicates the worst pain imaginable.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="1" upper_limit="76"/>
                    <measurement group_id="O2" value="32.5" lower_limit="0" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With the Essure Tubal Sterilization Procedure</title>
        <description>Patients reported their overall satisfaction with the Essure tubal sterilization procedure using a Visual Analog scale (VAS), range 0-100. A score of 0 indicates lowest possible satisfaction and a score of 100 indicates highest possible satisfaction.</description>
        <time_frame>30 minutes post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Group</title>
            <description>Participants receive transcervical instillation of 5 ml 4% lidocaine solution 3 minutes prior to transcervical tubal sterilization</description>
          </group>
          <group group_id="O2">
            <title>Saline Group</title>
            <description>Participants receive transcervical instillation of 5 ml saline 3 minutes prior to transcervical tubal sterilization</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With the Essure Tubal Sterilization Procedure</title>
          <description>Patients reported their overall satisfaction with the Essure tubal sterilization procedure using a Visual Analog scale (VAS), range 0-100. A score of 0 indicates lowest possible satisfaction and a score of 100 indicates highest possible satisfaction.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="46" upper_limit="100"/>
                    <measurement group_id="O2" value="93.5" lower_limit="66" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment to 30 minutes post-procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lidocaine Group</title>
          <description>Participants receive transcervical instillation of 5 ml 4% lidocaine solution 3 minutes prior to transcervical tubal sterilization</description>
        </group>
        <group group_id="E2">
          <title>Saline Group</title>
          <description>Participants receive transcervical instillation of 5 ml saline 3 minutes prior to transcervical tubal sterilization</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Difference in reported abortions between the two groups. Data not included on three subjects in saline group because the subjects could not tolerate the procedure.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Michelle Isley</name_or_title>
      <organization>The Ohio State University</organization>
      <phone>614-293-4203</phone>
      <email>Michelle.Isley@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

